Search results for: corticosteroids

Systemic Juvenile Idiopathic Arthritis

Rayfel Schneider, MBBCh, and Ronald M. Laxer, MDCM | May 9, 2012

Changing treatment paradigms in the biologic era

New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica

Kathy Holliman | April 6, 2012

The ACR has published three documents intended to provide clarity and consensus on management of osteoarthritis, classification criteria for Sjögren’s syndrome, and classification criteria for polymyalgia rheumatica. The documents, which represent the most current clinical evidence, research, and expert panel input and review, can help inform clinical practice and provide clearer target populations for future research.

Dermatology Case: History of ANCA–Associated Vasculitis, Fever, Rash

Joseph F. Merola, MD, Monica Ramirez, MD | April 6, 2012

A 66-year-old woman with a history of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis presents with two days of fever and rash.

Dermatology Case Answer: History of ANCA–Associated Vasculitis, Fever, Rash

Joseph F. Merola, MD, Monica Ramirez, MD | April 6, 2012

A 66-year-old woman with a history of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis presents with two days of fever and rash.

Treatment Patterns and Trends for Spondylarthropathies

Vanessa Caceres | April 6, 2012

Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.

The Mystery of IVIg

Eveline Wu, MD, Michael M. Frank, MD | March 8, 2012

Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.

Systemic Juvenile Idiopathic Arthritis

New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica

Dermatology Case: History of ANCA–Associated Vasculitis, Fever, Rash

Dermatology Case Answer: History of ANCA–Associated Vasculitis, Fever, Rash

Treatment Patterns and Trends for Spondylarthropathies

The Mystery of IVIg

Susac’s Syndrome: Confusion, Expressive Aphasia, Gait Instability

Information on New Drug Approvals and Medication Safety

A Short History of Rheumatoid Arthritis Therapeutics

Heroes